GLPwatch
Trials (2167)
Page 26 of 37.
- Menopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Diabetes
- Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes.
- Nutritional Therapy to Incretin-based Anti-obesity Medications in the Management of Gastrointestinal Adverse Events
- A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs
- Pemvidutide (ALT-801) DDI Study in Healthy Volunteers
- A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects
- Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS)
- Lifestyle Intervention to Reduce the Risk of Sarcopenia in Adults With Diabetes & Obesity Treated With Semaglutide
- Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects
- Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes
- Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy
- A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects
- Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1
- Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes
- A Study of Dulaglutide in Chinese Participants
- Role of Caveolin 1 (CAV-1) Deficiency in Response to Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Treatment
- Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome
- Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes
- Semaglutide in Treatment of Obesity
- A Study of Tirzepatide (LY3298176) in Healthy Lactating Females
- Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
- Assessing Follow up Trajectories in Eating, Routines, and Weight After GLP-1
- Semaglutide Use in Elderly Obese Patients
- A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People
- Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients
- The Differential Effects of Diabetes Therapy on Inflammation
- Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial Function
- Impact of Antiglycemic & Immunosuppressive Therapies on NETosis in Diabetes & Kidney Disease (NETs - Neutrophil Traps)
- Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes
- Monitoring Patients With Severe Obesity Treated With Wegovy® Using Connected Device: Real-world Data
- Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
- Clinical Study of 18F-Exendin-4 in Insulinoma
- Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus
- Semaglutide in Auto-HSCT
- Anti-diabetic Drugs and Fatty Liver Management
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
- A Study of IBI362 9 mg in Chinese Adults With Obesity
- Effects of GLP-1 Analogue Combined With Metformin and Metformin on Gonadal and Metabolic Profiles in Chinese Overweight/Obese PCOS Patients With Hyperandrogenemia.
- Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity
- Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia
- Safety, Tolerability, and Effectiveness of Duodenal Mucosal RF Vapor Ablation for Insulin Elimination in Type-2 Diabetes
- Effect of Tirzepatide on Markers of MASLD in Patients With Obesity
- Weight Loss in Adults Using Semaglutide (Real-world Study)
- A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice
- The Effect of Glucagon Like Peptide (GLP)-1 in Psoriasis
- A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
- Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
- A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus
- Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes
- Liraglutide in Type 1 Diabetes
- A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes
- Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus
- Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes Taking Twice-Daily Exenatide or Once-Weekly Exenatide
- SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary
- Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria
- A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes
- Optimization of Obesity for Total Knee Replacement With Glucagon-like Peptide-1 Receptor Agonist
- A Study of LY3841136 in Overweight and Obese Participants
- Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)